Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada.
Cannara Biotech Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.15|
|52 Week High||CA$0.075|
|52 Week Low||CA$0.18|
|1 Month Change||-11.77%|
|3 Month Change||-11.77%|
|1 Year Change||57.90%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-50.82%|
Recent News & Updates
|LOVE||CA Pharmaceuticals||CA Market|
Return vs Industry: LOVE exceeded the Canadian Pharmaceuticals industry which returned 37.4% over the past year.
Return vs Market: LOVE exceeded the Canadian Market which returned 32.3% over the past year.
Stable Share Price: LOVE is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: LOVE's weekly volatility (7%) has been stable over the past year.
About the Company
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. It also offers hemp-based CBD products through e-commerce platform. The company was incorporated in 2017 and is headquartered in Montreal, Canada.
Cannara Biotech Fundamentals Summary
|LOVE fundamental statistics|
Is LOVE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LOVE income statement (TTM)|
|Cost of Revenue||CA$5.81m|
Last Reported Earnings
May 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0089|
|Net Profit Margin||-57.34%|
How did LOVE perform over the long term?See historical performance and comparison
Is Cannara Biotech undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LOVE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LOVE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LOVE is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: LOVE is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LOVE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LOVE is overvalued based on its PB Ratio (3.6x) compared to the CA Pharmaceuticals industry average (2.6x).
How is Cannara Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannara Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Cannara Biotech performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: LOVE is currently unprofitable.
Growing Profit Margin: LOVE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LOVE's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LOVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LOVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (115.1%).
Return on Equity
High ROE: LOVE has a negative Return on Equity (-18%), as it is currently unprofitable.
How is Cannara Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: LOVE's short term assets (CA$13.9M) exceed its short term liabilities (CA$4.7M).
Long Term Liabilities: LOVE's short term assets (CA$13.9M) do not cover its long term liabilities (CA$16.7M).
Debt to Equity History and Analysis
Debt Level: LOVE's debt to equity ratio (44%) is considered high.
Reducing Debt: Insufficient data to determine if LOVE's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LOVE has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: LOVE is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.
What is Cannara Biotech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LOVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LOVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LOVE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LOVE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LOVE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Zohar Krivorot (44 yo)
Mr. Zohar Krivorot is Founder, President, Chief Executive Officer and Director at Cannara Biotech Inc. since December 31, 2018 and also serves as its Chairman. A successful entrepreneur, Mr. Krivorot has f...
CEO Compensation Analysis
Compensation vs Market: Zohar's total compensation ($USD72.84K) is below average for companies of similar size in the Canadian market ($USD161.20K).
Compensation vs Earnings: Zohar's compensation has been consistent with company performance over the past year.
Experienced Management: LOVE's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: LOVE's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LOVE insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.8%.
Cannara Biotech Inc.'s employee growth, exchange listings and data sources
- Name: Cannara Biotech Inc.
- Ticker: LOVE
- Exchange: TSXV
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$131.472m
- Shares outstanding: 876.48m
- Website: https://cannara.ca
Number of Employees
- Cannara Biotech Inc.
- 333 Decarie boulevard
- Suite 200
- H4N 3M9
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 23:09|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.